ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease
June 9, 2020
Tags:
ArcherDX will perform Whole Exome Sequencing of resected non-small cell lung cancer patient samples and generate patient-specific circulating tumor DNA assays.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
